Cytokinetics Names Robert E. Landry to Board of Directors
Cytokinetics (NASDAQ: CYTK) has appointed Robert E. Landry to its Board of Directors, bringing over three decades of pharmaceutical industry financial and operational expertise. Landry most recently served as Chief Financial Officer at Regeneron Pharmaceuticals for 11 years, where he managed financial operations, investor relations, IT, competitive intelligence, and global facilities.
During his tenure at Regeneron, Landry oversaw two public acquisitions (Checkmate Pharmaceuticals and Decibel Therapeutics) and helped establish global affiliates as the company experienced substantial market capitalization and workforce growth. Previously, he spent 25 years at Wyeth and Pfizer in various roles including Corporate Treasurer and CFO of Wyeth Australia and New Zealand.
The appointment comes as Cytokinetics approaches potential approval and launch of its first medicine, with the company aiming to become a fully integrated organization focused on sustainable growth.
Cytokinetics (NASDAQ: CYTK) ha nominato Robert E. Landry nel suo Consiglio di Amministrazione, portando con sé oltre tre decenni di esperienza finanziaria e operativa nel settore farmaceutico. Landry ha recentemente ricoperto il ruolo di Chief Financial Officer presso Regeneron Pharmaceuticals per 11 anni, dove ha gestito operazioni finanziarie, relazioni con gli investitori, IT, intelligence competitiva e strutture globali.
Durante il suo mandato in Regeneron, Landry ha supervisionato due acquisizioni pubbliche (Checkmate Pharmaceuticals e Decibel Therapeutics) e ha contribuito a stabilire filiali globali mentre l'azienda ha vissuto una significativa crescita della capitalizzazione di mercato e dell'organico. In precedenza, ha trascorso 25 anni in Wyeth e Pfizer in vari ruoli, tra cui Tesoriere Aziendale e CFO di Wyeth Australia e Nuova Zelanda.
La nomina avviene in un momento in cui Cytokinetics si avvicina a una potenziale approvazione e lancio del suo primo farmaco, con l'obiettivo aziendale di diventare un'organizzazione completamente integrata focalizzata sulla crescita sostenibile.
Cytokinetics (NASDAQ: CYTK) ha nombrado a Robert E. Landry en su Junta Directiva, aportando más de tres décadas de experiencia financiera y operativa en la industria farmacéutica. Landry se desempeñó recientemente como Director Financiero en Regeneron Pharmaceuticals durante 11 años, donde gestionó operaciones financieras, relaciones con inversores, IT, inteligencia competitiva y estructuras globales.
Durante su tiempo en Regeneron, Landry supervisó dos adquisiciones públicas (Checkmate Pharmaceuticals y Decibel Therapeutics) y ayudó a establecer afiliados globales a medida que la compañía experimentó un crecimiento sustancial en su capitalización de mercado y plantilla. Anteriormente, pasó 25 años en Wyeth y Pfizer en diversos roles, incluyendo Tesorero Corporativo y CFO de Wyeth en Australia y Nueva Zelanda.
El nombramiento llega mientras Cytokinetics se acerca a la posible aprobación y lanzamiento de su primer medicamento, con el objetivo de convertirse en una organización completamente integrada centrada en el crecimiento sostenible.
사이토키네틱스 (NASDAQ: CYTK)는 로버트 E. 랜드리를 이사회에 임명하여 제약 산업에서의 30년 이상의 재무 및 운영 전문성을 더했습니다. 랜드리는 최근 11년 동안 리제너론 제약에서 최고 재무 책임자(CFO)로 재직하며 재무 운영, 투자자 관계, IT, 경쟁 정보 및 글로벌 시설을 관리했습니다.
리제너론 재직 기간 동안 랜드리는 두 건의 공개 인수(체크메이트 제약 및 데시벨 치료제)를 감독하고, 회사가 상당한 시장 자본화와 인력 성장을 경험하는 동안 글로벌 자회사를 설립하는 데 도움을 주었습니다. 이전에는 와이어스(Wyeth)와 화이자(Pfizer)에서 25년을 다양한 역할로 보냈으며, 와이어스 호주 및 뉴질랜드의 기업 재무부장 및 CFO를 역임했습니다.
이 임명은 사이토키네틱스가 첫 번째 의약품의 잠재적 승인 및 출시를 앞두고 이루어지며, 지속 가능한 성장에 집중하는 완전 통합된 조직이 되는 것을 목표로 하고 있습니다.
Cytokinetics (NASDAQ: CYTK) a nommé Robert E. Landry au sein de son Conseil d'Administration, apportant plus de trois décennies d'expertise financière et opérationnelle dans l'industrie pharmaceutique. Landry a récemment occupé le poste de Directeur Financier chez Regeneron Pharmaceuticals pendant 11 ans, où il a géré les opérations financières, les relations avec les investisseurs, l'informatique, l'intelligence concurrentielle et les installations mondiales.
Au cours de son mandat chez Regeneron, Landry a supervisé deux acquisitions publiques (Checkmate Pharmaceuticals et Decibel Therapeutics) et a aidé à établir des filiales mondiales alors que l'entreprise connaître une croissance substantielle de sa capitalisation boursière et de ses effectifs. Auparavant, il a passé 25 ans chez Wyeth et Pfizer dans divers rôles, notamment Trésorier d'Entreprise et CFO de Wyeth Australie et Nouvelle-Zélande.
Cette nomination survient alors que Cytokinetics s'approche d'une éventuelle approbation et lancement de son premier médicament, l'entreprise visant à devenir une organisation complètement intégrée axée sur une croissance durable.
Cytokinetics (NASDAQ: CYTK) hat Robert E. Landry in seinen Vorstand berufen, der über mehr als drei Jahrzehnte Erfahrung in der Finanz- und Betriebswirtschaft der Pharmaindustrie verfügt. Landry war zuletzt 11 Jahre als Finanzvorstand (CFO) bei Regeneron Pharmaceuticals tätig, wo er für Finanzoperationen, Investor Relations, IT, Wettbewerbsanalysen und globale Einrichtungen verantwortlich war.
Während seiner Zeit bei Regeneron überwachte Landry zwei öffentliche Übernahmen (Checkmate Pharmaceuticals und Decibel Therapeutics) und half dabei, globale Tochtergesellschaften zu etablieren, während das Unternehmen eine erhebliche Kapitalisierung und Mitarbeiterwachstum erlebte. Zuvor verbrachte er 25 Jahre bei Wyeth und Pfizer in verschiedenen Positionen, darunter Unternehmensschatzmeister und CFO von Wyeth Australien und Neuseeland.
Die Ernennung erfolgt, da Cytokinetics der potenziellen Genehmigung und Markteinführung seines ersten Medikaments näher kommt, mit dem Ziel, ein vollwertiges Unternehmen zu werden, das sich auf nachhaltiges Wachstum konzentriert.
- Strategic timing of appointment coinciding with potential first product commercialization
- Addition of extensive financial expertise from successful pharma company scaling
- Board strengthening with experienced leadership in global pharmaceutical operations
- Expertise in managing substantial company growth and public acquisitions
- None.
Appointment Deepens Financial and Operational Expertise of Board
as Company Approaches Potential Commercialization
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having served as the Chief Financial Officer at Regeneron Pharmaceuticals Inc. for 11 years.
“We are pleased to have Bob join our Board as we approach a key shareholder value inflection point for the company and prepare for the potential approval and launch of our first medicine,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “His extensive career in finance and expertise spanning financial engineering, capital allocation and efficiencies, tax strategy and treasury management will be important as we advance toward commercialization. His leadership at Regeneron, guiding the company’s global scaling, while maintaining disciplined spending and a steadfast commitment to innovation in research and development, aligns with our vision at Cytokinetics of becoming a fully integrated company achieving sustainable growth.”
In his role as Chief Financial Officer at Regeneron, Mr. Landry was responsible for all financial operations as well as investor relations, information technology, competitive intelligence and global non-manufacturing facilities, helping guide the company as it grew substantially in market capitalization and workforce over more than a decade. During his tenure he oversaw two public acquisitions, Checkmate Pharmaceuticals and Decibel Therapeutics, and established affiliates around the world.
Prior to joining Regeneron, Mr. Landry spent 25 years at Wyeth and Pfizer Inc., where he held numerous corporate and operational roles including Corporate Treasurer, Senior Vice President of Finance, Director of Pharmaceutical Marketing and Sales, and Chief Financial Officer of Wyeth Australia and New Zealand. Mr. Landry started his career at Coopers & Lybrand, now PricewaterhouseCoopers LLP. He was a Certified Public Accountant in New York and received a Bachelor of Business Administration from the University of Notre Dame.
About Cytokinetics
Cytokinetics is a late-stage, muscle biology specialty biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, Cytokinetics is intent on meaningfully improving the lives of patients through global access to innovative medicines. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a potential next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
What experience does Robert Landry bring to CYTK's Board of Directors?
Why did Cytokinetics (CYTK) appoint Robert Landry to its board in February 2024?
What major acquisitions did Robert Landry oversee at Regeneron before joining CYTK's board?
What is the strategic significance of CYTK's new board appointment?
